Clinical Trials Logo

Clinical Trial Summary

Fifty patients with pathological proof of malignant soft tissue sarcoma will receive Anthracyclin based chemotherapy combined with propranolol 40 mg twice daily.

- The primary end point : To assess Progression Free Survival (PFS)

- The secondary end points : To assess Overall Survival (OS) and Toxicity Profile


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03108300
Study type Interventional
Source Ain Shams University
Contact
Status Not yet recruiting
Phase Phase 2
Start date August 30, 2019
Completion date August 30, 2021